查看文章

Acute myeloid leukemia (AML) is a heterogeneous group of hematologic malignancies characterized by the proliferation of myeloid cells blocked in their ability to differentiate. Evaluation by G-banding and fluorescence in situ hybridization is an essential aspect in the initial disease characterization and even now is fundamental in identifying cytogenetic abnormalities that can inform disease diagnosis, prognosis, and treatment decision [1, 2]. For instance, the identification of t (8; 21)(q22; q22) or t (15; 17)(q22; q12), which generate RUNX1-RUNX1T1 or PML-RARA gene fusions, respectively, confers favorable prognosis when treated accordingly [1]. In recent years, advancements in next-generation sequencing and efforts by large genomics studies have led to a classification of 11 AML subgroups based on cytogenetic abnormalities as well as mutations in genes, such as NPM1 or CEBPA [1]. AML with a complex …